Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
about
Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65-/- knockout mouse eye results in limited rescueIn utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical applicationHemophilia A: an ideal disease to correct in uteroIn vivo delivery of recombinant viruses to the fetal murine cochlea: transduction characteristics and long-term effects on auditory function.Haemophilia B: from molecular diagnosis to gene therapy.Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.Immune responses to adeno-associated virus and its recombinant vectors.Perinatal gene transfer to the liver.A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculationTreatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene DeliveryRole of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hF.IX.Proteases as therapeutics.Fetal gene therapy: recent advances and current challenges.Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque.Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice.Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors.Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease.
P2860
Q24802168-5527BEC0-5C07-4E34-BDCC-6F3B6DD31C8BQ26748949-14C59666-A5C1-4596-BA5E-2A229694EC1EQ26852638-FEF2AADB-3CFE-4B85-A29E-84E765CD34A3Q30584770-03F0FC42-34C1-4F89-B8E0-55FE77B7B49FQ35127766-24072700-6DD1-46DF-A2AC-F15069325BA9Q35131227-BF0B930D-9B0C-4004-B9E2-A08ED72D5F92Q35131229-F9B2F90A-A0CB-4E86-8A6D-2982FFE62EC4Q35238390-46424748-E8D3-40D9-B29F-41008E655E79Q35543174-55BCC5BB-1868-4D4C-9F35-6AC143959F40Q36477364-8CD373E6-F2B1-4B63-89B1-593E87AD77B9Q37226788-B605EB58-E3CF-4E14-A927-3529BFFFECEFQ37853216-935B6A65-8E6C-49B1-BAD0-F4806B5F7B60Q37881971-3DFB15D3-8A34-4F82-A59F-0CF16DC5DAC2Q42469138-63EA702E-93A9-4935-B953-56775F926DA0Q42690486-B5E3101C-8124-4410-8000-66102D75DB18Q44536266-28C3DE6A-CD86-49FD-B967-EFF1D799D585Q44576919-0CBCD3C1-D50D-4C68-982E-FAC3345AF5C3Q45861357-75B870DD-BDFF-41CC-A48B-A9DB7AA20B6A
P2860
Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Sustained delivery of therapeu ...... vectors administered in utero.
@en
Sustained delivery of therapeu ...... vectors administered in utero.
@nl
type
label
Sustained delivery of therapeu ...... vectors administered in utero.
@en
Sustained delivery of therapeu ...... vectors administered in utero.
@nl
prefLabel
Sustained delivery of therapeu ...... vectors administered in utero.
@en
Sustained delivery of therapeu ...... vectors administered in utero.
@nl
P2093
P2860
P356
P1476
Sustained delivery of therapeu ...... vectors administered in utero.
@en
P2093
Anne Marie Douar
Charles Coutelle
Christiane Mühle
Holm Schneider
Klaus von der Mark
Qiu-Jie Jiang
Wolfgang Rascher
P2860
P356
10.1002/JGM.233
P577
2002-01-01T00:00:00Z